ATE401348T1 - Immunokonjugate mit hoher bindungsaffinität - Google Patents
Immunokonjugate mit hoher bindungsaffinitätInfo
- Publication number
- ATE401348T1 ATE401348T1 AT00937925T AT00937925T ATE401348T1 AT E401348 T1 ATE401348 T1 AT E401348T1 AT 00937925 T AT00937925 T AT 00937925T AT 00937925 T AT00937925 T AT 00937925T AT E401348 T1 ATE401348 T1 AT E401348T1
- Authority
- AT
- Austria
- Prior art keywords
- mesothelin
- antibodies
- immunoconjugates
- present
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16007199P | 1999-05-27 | 1999-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401348T1 true ATE401348T1 (de) | 2008-08-15 |
Family
ID=22575396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00937925T ATE401348T1 (de) | 1999-05-27 | 2000-05-26 | Immunokonjugate mit hoher bindungsaffinität |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7081518B1 (de) |
| EP (2) | EP2011801A1 (de) |
| JP (3) | JP5683766B2 (de) |
| AT (1) | ATE401348T1 (de) |
| AU (1) | AU5303700A (de) |
| CA (1) | CA2374398C (de) |
| DE (1) | DE60039510D1 (de) |
| DK (1) | DK1180123T3 (de) |
| MX (1) | MXPA01011950A (de) |
| WO (1) | WO2000073346A1 (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ATE474854T1 (de) * | 2000-01-27 | 2010-08-15 | Medimmune Llc | Rsv neutralisierende antikörper mit sehr hohen affinität |
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP2305710A3 (de) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetische Antikörperphagenbibliotheken |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| AU2003248744C1 (en) * | 2002-06-28 | 2009-12-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors |
| US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
| WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| ATE468356T1 (de) | 2003-11-25 | 2010-06-15 | Us Gov Health & Human Serv | Mutierte anti-cd22-antikörper und immunkonjugate |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP1861425B1 (de) * | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin-antikörper |
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1885758A2 (de) * | 2005-05-12 | 2008-02-13 | The Government of the United States of America as Represented by The Department of Health and Human Services | Für immunologische assays geeignete anti-mesothelin-antikörper |
| EP3006456B1 (de) * | 2005-07-29 | 2018-09-19 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutierte pseudomonas exotoxine mit reduzierter antigenizität |
| BRPI0807952A2 (pt) * | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
| CA2698357C (en) * | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP2257572A1 (de) | 2008-03-27 | 2010-12-08 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Monoklonale menschliche mesothelin-antikörper |
| WO2010045495A2 (en) | 2008-10-16 | 2010-04-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| EP2475398B1 (de) | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Verbessertes pseudomonas-exotoxin a mit verminderter immunogenität |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
| JP2013538042A (ja) | 2010-06-16 | 2013-10-10 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | エンドプラスミンに対する抗体およびその使用 |
| WO2012087962A2 (en) | 2010-12-20 | 2012-06-28 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| CN103596985B (zh) | 2011-04-19 | 2016-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| BR112013028537A2 (pt) | 2011-05-06 | 2017-01-17 | Us Gov Health & Human Serv | imunotoxina recombinante que visa a mesotelina |
| EP3231812B1 (de) | 2011-06-09 | 2020-03-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen t-zell- und/oder b-zellepitopen |
| PL2755993T3 (pl) | 2011-09-16 | 2018-04-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Egzotoksyna A Pseudomonas z mniej immunogennymi epitopami komórek B |
| US9359447B2 (en) | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP2888282B1 (de) | 2012-08-21 | 2018-03-14 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Domänenspezifische monoklonale mesothelin-antikörper und verwendung davon |
| JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
| US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
| JP6584012B2 (ja) | 2013-10-06 | 2019-10-02 | アメリカ合衆国 | 改変シュードモナス外毒素ａ |
| GB201500464D0 (en) | 2015-01-12 | 2015-02-25 | Crescendo Biolog Ltd | Method of producing optimised therapeutic molecules |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| TW201831513A (zh) | 2016-06-20 | 2018-09-01 | Ｆ星貝塔有限公司 | 結合物件(一) |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| EP3544996A2 (de) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen |
| EP3638295A1 (de) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| US11795235B2 (en) | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
| JP6339283B1 (ja) * | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| EP3707160A1 (de) | 2017-11-10 | 2020-09-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Gegen tumorantigene gerichtete chimäre antigenrezeptoren |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Ｔｃｒ２療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
| CA3115150A1 (en) * | 2018-10-22 | 2020-04-30 | Fusion Antibodies Plc | Antibody library and method |
| CN109517070A (zh) * | 2018-11-07 | 2019-03-26 | 南京卡提医学科技有限公司 | 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-TREM1及其用途 |
| EP3883608A1 (de) | 2019-01-08 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren |
| KR20230021018A (ko) * | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| EP4178985A1 (de) | 2020-07-10 | 2023-05-17 | F. Hoffmann-La Roche AG | An krebszellen bindende antikörper und target-radionuklide an diese zellen |
| WO2022098797A1 (en) * | 2020-11-04 | 2022-05-12 | Fred Hutchinson Cancer Research Center | Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy |
| WO2022152701A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
| KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
| AU2022416639A1 (en) | 2021-12-17 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
| WO2025171238A1 (en) | 2024-02-07 | 2025-08-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof |
| WO2025240496A1 (en) | 2024-05-14 | 2025-11-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| ES2121792T3 (es) | 1990-10-12 | 1998-12-16 | Us Health | Anticuerpo monoclonal. |
| JP3328341B2 (ja) | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
| IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| ATE483733T1 (de) * | 1995-06-14 | 2010-10-15 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| AU703769B2 (en) | 1996-01-05 | 1999-04-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Mesothelium antigen and methods and kits for targeting it |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
-
2000
- 2000-05-26 AT AT00937925T patent/ATE401348T1/de not_active IP Right Cessation
- 2000-05-26 EP EP08012813A patent/EP2011801A1/de not_active Withdrawn
- 2000-05-26 DK DK00937925T patent/DK1180123T3/da active
- 2000-05-26 CA CA2374398A patent/CA2374398C/en not_active Expired - Lifetime
- 2000-05-26 DE DE60039510T patent/DE60039510D1/de not_active Expired - Lifetime
- 2000-05-26 JP JP2001500670A patent/JP5683766B2/ja not_active Expired - Lifetime
- 2000-05-26 US US09/979,539 patent/US7081518B1/en not_active Expired - Lifetime
- 2000-05-26 EP EP00937925A patent/EP1180123B1/de not_active Expired - Lifetime
- 2000-05-26 MX MXPA01011950A patent/MXPA01011950A/es active IP Right Grant
- 2000-05-26 AU AU53037/00A patent/AU5303700A/en not_active Abandoned
- 2000-05-26 WO PCT/US2000/014829 patent/WO2000073346A1/en not_active Ceased
-
2011
- 2011-12-08 JP JP2011269272A patent/JP2012050464A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013257556A patent/JP2014050409A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01011950A (es) | 2002-05-06 |
| AU5303700A (en) | 2000-12-18 |
| JP2003502030A (ja) | 2003-01-21 |
| DE60039510D1 (de) | 2008-08-28 |
| EP1180123B1 (de) | 2008-07-16 |
| CA2374398C (en) | 2011-03-15 |
| DK1180123T3 (da) | 2008-10-13 |
| JP2014050409A (ja) | 2014-03-20 |
| US7081518B1 (en) | 2006-07-25 |
| JP5683766B2 (ja) | 2015-03-11 |
| CA2374398A1 (en) | 2000-12-07 |
| WO2000073346A1 (en) | 2000-12-07 |
| JP2012050464A (ja) | 2012-03-15 |
| EP2011801A1 (de) | 2009-01-07 |
| EP1180123A1 (de) | 2002-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60039510D1 (de) | Immunokonjugate mit hoher bindungsaffinität | |
| IL135775A0 (en) | Antibodies and immunoconjugates having high binding affinity for mesothelin | |
| Fang et al. | Structurally defined αMHC‐II nanobody–drug conjugates: a therapeutic and imaging system for B‐cell lymphoma | |
| ATE382370T1 (de) | Antikörper-serumprotein hybride | |
| DE69632401D1 (de) | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung | |
| EE04752B1 (et) | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine | |
| GR1000712B (el) | Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα. | |
| BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
| EP1090924A4 (de) | Von cyclophilin b abstammende tumorantigen-peptide | |
| DE69838979D1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| EA200100224A1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| RU94045281A (ru) | Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата | |
| HUP0102992A3 (en) | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis | |
| CY1111193T1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
| BR9508402A (pt) | Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união | |
| ATE420175T1 (de) | C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen | |
| FI950062A0 (fi) | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten | |
| RU92016354A (ru) | Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата | |
| EP1207199A4 (de) | Tumor antigen | |
| NZ326436A (en) | Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors | |
| DE59712259D1 (de) | E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren | |
| DE69829001D1 (de) | Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 | |
| EA200100311A1 (ru) | Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств | |
| Bidard et al. | Trends in cancer-targeted antibody–drug conjugates | |
| DE69724761D1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |